BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
March 01 2024 - 7:00AM
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical
company utilizing artificial intelligence to develop transformative
medicines in neuroscience and immuno-oncology, today announced that
it will release its fourth quarter and full year 2023 financial
results on Tues., March 12, 2024, before the open of the U.S.
financial markets. BioXcel Therapeutics’ management team will also
host a conference call and webcast at 8:00 AM ET that day to
discuss the Company’s financial results and provide a general
business update.
Conference
Call & Webcast Details |
|
|
Date/Time: |
Tues., March 12, 2024, at 8:00 AM
ET |
Domestic: |
877-407-5795 |
International: |
201-689-8722 |
The webcast link will be accessible under “News/Events” on the
Investors & Media page of the Company's website
at www.bioxceltherapeutics.com.
Replay* |
|
Domestic: |
877-660-6853 |
International: |
201-612-7415 |
Conference
ID: |
13744874 |
|
|
*Replay available through June 12, 2024
About BioXcel Therapeutics, Inc.BioXcel
Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company
utilizing artificial intelligence to develop transformative
medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel
Therapeutics, is focused on the development of medicines in
immuno-oncology. The Company’s drug re-innovation approach
leverages existing approved drugs and/or clinically validated
product candidates together with big data and proprietary machine
learning algorithms to identify new therapeutic indications. For
more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements
contained in this press release other than statements of historical
fact should be considered forward-looking statements, including,
without limitation, the date and time of the release of Company’s
fourth quarter and full year 2023 financial results and related
conference call. When used herein, words including “anticipate,”
“believe,” “can,” “continue,” “could,” “designed,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “target,”
“will,” “would” and similar expressions are intended to identify
forward-looking statements, though not all forward-looking
statements use these words or expressions. In addition, any
statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon the Company’s current expectations and
various assumptions. The Company believes there is a reasonable
basis for its expectations and beliefs, but they are inherently
uncertain. The Company may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation, the important factors discussed under the
caption “Risk Factors” in its Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2023, as such factors may be
updated from time to time in its other filings with the SEC,
including without limitation its Annual Report on Form 10-K for the
fiscal year ended December 31, 2023, which are accessible on the
SEC’s website at www.sec.gov. These and other important factors
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While the Company
may elect to update such forward-looking statements at some point
in the future, except as required by law, it disclaims any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon
as representing the Company’s views as of any date subsequent to
the date of this press release.
Contact Information
Corporate
BioXcel TherapeuticsErik
Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
BioXcel TherapeuticsBrennan
Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media
Russo PartnersDavid
Schull1.858-717-2310David.schull@russopartnersllc.comScott
Stachowiak1.646-942-5630Scott.stachowiak@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel
Therapeutics, Inc. All other trademarks are the properties of their
respective owners.Copyright © 2024, BioXcel Therapeutics, Inc. All
rights reserved.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Jul 2023 to Jul 2024